Annual EBIT
-$13.95 M
-$20.28 M-320.45%
31 December 2023
Summary:
Vanda Pharmaceuticals annual earnings before interest & taxes is currently -$13.95 million, with the most recent change of -$20.28 million (-320.45%) on 31 December 2023. During the last 3 years, it has fallen by -$41.19 million (-151.22%). VNDA annual EBIT is now -133.09% below its all-time high of $45.01 million.VNDA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$11.00 M
-$854.00 K-8.42%
30 September 2024
Summary:
Vanda Pharmaceuticals quarterly earnings before interest & taxes is currently -$11.00 million, with the most recent change of -$854.00 thousand (-8.42%) on 30 September 2024. Over the past year, it has dropped by -$5.00 million (-83.49%). VNDA quarterly EBIT is now -188.93% below its all-time high of $12.37 million, reached on 30 June 2021.VNDA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$37.48 M
-$5.00 M-15.41%
30 September 2024
Summary:
Vanda Pharmaceuticals TTM earnings before interest & taxes is currently -$37.48 million, with the most recent change of -$5.00 million (-15.41%) on 30 September 2024. Over the past year, it has dropped by -$37.25 million (-16264.63%). VNDA TTM EBIT is now -185.21% below its all-time high of $43.98 million, reached on 30 September 2021.VNDA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VNDA EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -320.4% | -83.5% | -10000.0% |
| 3 y3 years | -151.2% | -201.7% | -185.2% |
| 5 y5 years | -164.2% | -202.2% | -235.2% |
VNDA EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -133.1% | at low | -201.7% | at low | -185.2% | at low |
| 5 y | 5 years | -133.1% | at low | -188.9% | at low | -185.2% | at low |
| alltime | all time | -133.1% | +81.2% | -188.9% | +58.6% | -185.2% | +51.5% |
Vanda Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$11.00 M(+8.4%) | -$37.48 M(+15.4%) |
| June 2024 | - | -$10.15 M(+9.9%) | -$32.47 M(+28.9%) |
| Mar 2024 | - | -$9.23 M(+30.2%) | -$25.19 M(+80.6%) |
| Dec 2023 | -$13.95 M(-320.4%) | -$7.09 M(+18.3%) | -$13.95 M(+5992.6%) |
| Sept 2023 | - | -$6.00 M(+109.1%) | -$229.00 K(-102.4%) |
| June 2023 | - | -$2.87 M(-243.1%) | $9.67 M(-39.5%) |
| Mar 2023 | - | $2.00 M(-69.8%) | $16.00 M(+152.8%) |
| Dec 2022 | $6.33 M(-85.0%) | $6.63 M(+69.6%) | $6.33 M(-24.1%) |
| Sept 2022 | - | $3.91 M(+12.9%) | $8.34 M(-45.3%) |
| June 2022 | - | $3.46 M(-145.1%) | $15.25 M(-36.9%) |
| Mar 2022 | - | -$7.67 M(-188.8%) | $24.16 M(-42.7%) |
| Dec 2021 | $42.16 M(+54.8%) | $8.64 M(-20.2%) | $42.16 M(-4.1%) |
| Sept 2021 | - | $10.82 M(-12.5%) | $43.98 M(+7.5%) |
| June 2021 | - | $12.37 M(+19.6%) | $40.90 M(+8.5%) |
| Mar 2021 | - | $10.34 M(-1.1%) | $37.70 M(+38.4%) |
| Dec 2020 | $27.24 M(+19.4%) | $10.45 M(+35.0%) | $27.24 M(+29.5%) |
| Sept 2020 | - | $7.74 M(-15.6%) | $21.03 M(-12.5%) |
| June 2020 | - | $9.17 M(-7436.8%) | $24.05 M(-2.9%) |
| Mar 2020 | - | -$125.00 K(-102.9%) | $24.77 M(+8.6%) |
| Dec 2019 | $22.81 M(+4.9%) | $4.24 M(-60.6%) | $22.81 M(-17.7%) |
| Sept 2019 | - | $10.76 M(+8.7%) | $27.72 M(+19.5%) |
| June 2019 | - | $9.89 M(-574.1%) | $23.19 M(+34.8%) |
| Mar 2019 | - | -$2.09 M(-122.8%) | $17.21 M(-20.8%) |
| Dec 2018 | $21.74 M(-228.6%) | $9.15 M(+46.8%) | $21.74 M(+108.3%) |
| Sept 2018 | - | $6.23 M(+59.3%) | $10.44 M(-1553.8%) |
| June 2018 | - | $3.91 M(+60.2%) | -$718.00 K(-89.0%) |
| Mar 2018 | - | $2.44 M(-213.6%) | -$6.55 M(-61.2%) |
| Dec 2017 | -$16.90 M(-9.0%) | -$2.15 M(-56.3%) | -$16.90 M(+9.7%) |
| Sept 2017 | - | -$4.92 M(+155.9%) | -$15.41 M(+38.3%) |
| June 2017 | - | -$1.92 M(-75.7%) | -$11.14 M(-20.5%) |
| Mar 2017 | - | -$7.91 M(+1108.9%) | -$14.00 M(-24.6%) |
| Dec 2016 | -$18.57 M(-53.8%) | -$654.00 K(+0.2%) | -$18.57 M(-43.4%) |
| Sept 2016 | - | -$653.00 K(-86.4%) | -$32.81 M(-21.3%) |
| June 2016 | - | -$4.79 M(-61.6%) | -$41.70 M(-1.6%) |
| Mar 2016 | - | -$12.47 M(-16.2%) | -$42.37 M(+5.4%) |
| Dec 2015 | -$40.19 M(-30.2%) | -$14.89 M(+56.1%) | -$40.19 M(+21.0%) |
| Sept 2015 | - | -$9.54 M(+74.8%) | -$33.22 M(+32.2%) |
| June 2015 | - | -$5.46 M(-47.0%) | -$25.12 M(-39.1%) |
| Mar 2015 | - | -$10.29 M(+29.9%) | -$41.27 M(-28.3%) |
| Dec 2014 | -$57.55 M | -$7.92 M(+447.2%) | -$57.55 M(+0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2014 | - | -$1.45 M(-93.3%) | -$57.42 M(-6.5%) |
| June 2014 | - | -$21.61 M(-18.7%) | -$61.41 M(+42.1%) |
| Mar 2014 | - | -$26.58 M(+241.1%) | -$43.21 M(+103.8%) |
| Dec 2013 | -$21.20 M(-27.3%) | -$7.79 M(+43.5%) | -$21.20 M(+2.0%) |
| Sept 2013 | - | -$5.43 M(+59.1%) | -$20.79 M(+0.2%) |
| June 2013 | - | -$3.41 M(-25.2%) | -$20.75 M(-18.4%) |
| Mar 2013 | - | -$4.57 M(-38.2%) | -$25.43 M(-12.9%) |
| Dec 2012 | -$29.18 M(+172.5%) | -$7.38 M(+36.8%) | -$29.18 M(+5.3%) |
| Sept 2012 | - | -$5.39 M(-33.3%) | -$27.70 M(+8.2%) |
| June 2012 | - | -$8.09 M(-2.8%) | -$25.60 M(+34.5%) |
| Mar 2012 | - | -$8.32 M(+40.8%) | -$19.03 M(+77.7%) |
| Dec 2011 | -$10.71 M(-221.1%) | -$5.91 M(+79.4%) | -$10.71 M(+167.1%) |
| Sept 2011 | - | -$3.29 M(+117.6%) | -$4.01 M(<-9900.0%) |
| June 2011 | - | -$1.51 M(<-9900.0%) | $28.00 K(-99.0%) |
| Mar 2011 | - | $7000.00(-99.1%) | $2.70 M(-69.5%) |
| Dec 2010 | $8.84 M(-124.6%) | $791.00 K(+6.5%) | $8.84 M(-839.5%) |
| Sept 2010 | - | $743.00 K(-35.8%) | -$1.20 M(-87.6%) |
| June 2010 | - | $1.16 M(-81.2%) | -$9.67 M(-58.4%) |
| Mar 2010 | - | $6.15 M(-166.5%) | -$23.24 M(-35.3%) |
| Dec 2009 | -$35.95 M(-32.0%) | -$9.24 M(+19.5%) | -$35.95 M(+4.6%) |
| Sept 2009 | - | -$7.74 M(-37.7%) | -$34.36 M(-9.1%) |
| June 2009 | - | -$12.41 M(+89.3%) | -$37.82 M(-3.9%) |
| Mar 2009 | - | -$6.56 M(-14.3%) | -$39.34 M(-25.6%) |
| Dec 2008 | -$52.85 M(-28.6%) | -$7.65 M(-31.6%) | -$52.85 M(-13.7%) |
| Sept 2008 | - | -$11.19 M(-19.7%) | -$61.26 M(-16.8%) |
| June 2008 | - | -$13.94 M(-30.5%) | -$73.59 M(-4.8%) |
| Mar 2008 | - | -$20.06 M(+24.8%) | -$77.30 M(+4.4%) |
| Dec 2007 | -$74.06 M(+12.7%) | -$16.07 M(-31.7%) | -$74.06 M(+5.2%) |
| Sept 2007 | - | -$23.52 M(+33.3%) | -$70.40 M(+18.0%) |
| June 2007 | - | -$17.64 M(+4.9%) | -$59.68 M(-6.9%) |
| Mar 2007 | - | -$16.83 M(+35.6%) | -$64.12 M(-2.4%) |
| Dec 2006 | -$65.71 M(+170.6%) | -$12.41 M(-3.1%) | -$65.71 M(+8.9%) |
| Sept 2006 | - | -$12.81 M(-42.0%) | -$60.36 M(+13.2%) |
| June 2006 | - | -$22.08 M(+19.9%) | -$53.31 M(+45.0%) |
| Mar 2006 | - | -$18.41 M(+160.9%) | -$36.76 M(+51.4%) |
| Dec 2005 | -$24.29 M(+154.9%) | -$7.06 M(+22.6%) | -$24.29 M(+41.0%) |
| Sept 2005 | - | -$5.76 M(+4.0%) | -$17.23 M(+50.2%) |
| June 2005 | - | -$5.53 M(-6.8%) | -$11.47 M(+93.2%) |
| Mar 2005 | - | -$5.94 M | -$5.94 M |
| Dec 2004 | -$9.53 M | - | - |
FAQ
- What is Vanda Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals annual EBIT year-on-year change?
- What is Vanda Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals quarterly EBIT year-on-year change?
- What is Vanda Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Vanda Pharmaceuticals?
- What is Vanda Pharmaceuticals TTM EBIT year-on-year change?
What is Vanda Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of VNDA is -$13.95 M
What is the all time high annual EBIT for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high annual earnings before interest & taxes is $45.01 M
What is Vanda Pharmaceuticals annual EBIT year-on-year change?
Over the past year, VNDA annual earnings before interest & taxes has changed by -$20.28 M (-320.45%)
What is Vanda Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of VNDA is -$11.00 M
What is the all time high quarterly EBIT for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high quarterly earnings before interest & taxes is $12.37 M
What is Vanda Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, VNDA quarterly earnings before interest & taxes has changed by -$5.00 M (-83.49%)
What is Vanda Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of VNDA is -$37.48 M
What is the all time high TTM EBIT for Vanda Pharmaceuticals?
Vanda Pharmaceuticals all-time high TTM earnings before interest & taxes is $43.98 M
What is Vanda Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, VNDA TTM earnings before interest & taxes has changed by -$37.25 M (-16264.63%)